The cell therapy revolution has changed the face of cancer treatments providing potentially curative therapy for patients which had few options left. Driving on this success, the time has come to redirect and focus attention to solid tumor indications, to meet the needs of this huge patient population and provide a cure for those extremely difficult to treat tumors.

90% of cancers arise from solid tumors. Now is the time to join the race to achieve clinical success with cellular immunotherapies and claim your stake of this vast untapped market.